|
Partnering is a fundamental part of POZEN’s
Business Development strategy. Through
partnering, we intend to 1) supplement our
self-innovated development portfolio by
in-licensing new product candidates, and 2)
out-license our progressed candidates to
corporate partners for commercialization.
In-Licensing
We seek to in-license
early-stage clinical compounds in the pain
area where POZEN utilizes strategic
outsourcing to efficiently develop products
through Phase III. We may also consider
certain pre-clinical stage compounds that
will complement our pain product portfolio,
and meet our new product criteria:
POZEN’s New Product Criteria
- A sound commercial
and scientific opportunity
- Low risk profile
(clinical data preferred)
- Manageable cash
outlay for development
- Ideally a
development program of 4 years or less
- Known endpoints
for regulatory development
POZEN seeks in-licensing agreements which
optimize the value of our assets and allow
both POZEN and its partner to jointly
benefit from commercialization success. Our
in-licensing deal structures include
traditional upfront/milestone payments and
royalties on future net sales. We also have
an innovative License-back Model in
which the originator company maintains an
option to reacquire the compound on
predetermined terms when the compound is
closer to market – i.e., when the
development risk has been significantly
reduced and the commercial potential can be
better defined.
Click for a larger diagram
Out-Licensing
POZEN intends to advance the development of all our
product candidates through Phase III, and commercialize products through
strategic alliances with industry partners.
We are currently seeking to out-license PA32540 (Phase II, "Safer
Aspirin").
As
a prospective partner, we hope you will fully explore what POZEN has to
offer and contact us if there is an opportunity for us to work together.
AstraZeneca Collaboration
POZEN
entered into a collaboration agreement with AstraZeneca on August 1,
2006 for the co-development and commercialization of proprietary fixed
dose combinations of the proton pump inhibitor (PPI) esomeprazole
magnesium, with the non-steroidal anti-inflammatory drug (NSAID)
naproxen, in a single tablet. This
is the basis for the PN 400 program. The
products will be indicated for the relief of the signs and symptoms
associated with conditions such as osteoarthritis and rheumatoid
arthritis in patients who are at risk for developing NSAID-associated
gastric ulcers. In September 2007,
POZEN and AstraZeneca amended certain terms of the August 2006
collaboration agreement. AstraZeneca will pay POZEN up to $345 million,
in aggregate, for the achievement of development, regulatory, and sales
milestones. POZEN received $30 million, which included recognition of
successful proof of concept, $55 million will be paid upon achievement
of certain development and regulatory milestones, and $260 will be paid
as sales performance milestones if certain aggregate sales thresholds
are achieved. In addition, POZEN will receive royalties on net sales.
GlaxoSmithkline
Collaboration
In April 2008, the successful collaboration between POZEN and
GlaxoSmithKline (GSK) culminated in the approval of
Treximet™.
The partnership began in 2003, when GSK signed an agreement with POZEN
Inc. for the development and commercialization of this combination
product. The deal terms include $80 million in upfront and certain
development and regulatory milestone payments and an additional $80
million in sales performance milestones based on achievement of certain
sales thresholds. Additionally, POZEN will receive royalties based on
net sales. Treximet is expected to be available in U.S.
pharmacies by mid-May. |
